Up next

Autoplay

Immune checkpoint inhibitor combination efficacious for patients with high-grade neuroendocrine ...

3 Views • 07/08/23
Share
Embed
administrator
administrator
Subscribers
0

Prof Sandip Patel gives a press conference at AACR 2019 on results from the DART phase II trial which showed the combination of ipilimumab and nivolumab to have clinical benefit when treating high-grade neuroendocrine carcinoma.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay